




2-{4-[(N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl)amino]butoxy}-6-hydroxybenzoate



2-{4-[(N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl)amino]butoxy}-6-hydroxybenzoate



chain nodes :

7 8 9 10 11 12 13 14 15 16 17 18 19 20 27 28 29 30 37 38 39 40 41 42
 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
 66 67 68 69 70 71

ring nodes :

1 2 3 4 5 6 21 22 23 24 25 26 31 32 33 34 35 36

chain bonds :

1-70 2-69 3-46 4-43 5-7 6-71 7-8 8-9 8-67 8-68 9-10 9-65 9-66 10-11 10-63
 10-64 11-12 11-61 11-62 12-13 12-47 13-14 13-15 15-16 15-17 15-59 16-21 16-57
 16-58 17-18 17-60 18-19 18-20 22-54 23-27 24-29 25-55 26-56 27-28 27-48 27-49
 29-30 29-31 30-37 30-38 32-50 33-51 34-52 35-53 36-41 38-39 38-40 40-42 43-44
 43-45

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-26 22-23 23-24 24-25 25-26 31-32 31-36 32-33
 33-34 34-35 35-36

exact/norm bonds :

3-46 5-7 7-8 11-12 12-13 13-14 15-17 17-18 18-19 24-29 29-30 29-31 30-37 43-44
 43-45

exact bonds :

1-70 2-69 4-43 6-71 8-9 8-67 8-68 9-10 9-65 9-66 10-11 10-63 10-64 11-61
 11-62 12-47 13-15 15-16 15-59 16-21 16-57 16-58 17-60 18-20 22-54 23-27 25-55
 26-56 27-28 27-48 27-49 30-38 32-50 33-51 34-52 35-53 36-41 40-42

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-26 22-23 23-24 24-25 25-26 31-32 31-36 32-33
 33-34 34-35 35-36 38-39 38-40

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:CLASS
 29:CLASS 30:CLASS 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:CLASS
 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS
 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS
 56:CLASS

57:CLASS 58:CLASS 59:CLASS 60:CLASS 61:CLASS CLASS 63:CLASS 64:CLASS
65:CLASS 66:CLASS 67:CLASS 68:CLASS 69:CLASS 70:CLASS 71:CLASS

L6 2 SEA SSS FUL L5

L7 2 L6

=> d 17 1-2 ibib abs hitstr

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:869580 CAPLUS

DOCUMENT NUMBER: 137:353320

TITLE: Preparation of amino(oxo)acetic acid derivatives as selective protein tyrosine phosphatase inhibitors
INVENTOR(S): Liu, Gang; Xin, Zhili; Pei, Zhonghua; Li, Xiaofeng; Szczepankiewicz, Bruce G.; Janowick, David A.; Oost, Thorsten K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Pat. Appl. 2002 72,516.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002169157	A1	20021114	US 2002-85157	20020227
US 2002035137	A1	20020321	US 2001-918928	20010731
US 2002072516	A1	20020613	US 2001-941471	20010829
PRIORITY APPLN. INFO.:			US 2000-228651P	P 20000829
			US 2000-650922	A2 20000829
			US 2001-918928	A2 20010731
			US 2001-941471	A2 20010829

OTHER SOURCE(S): MARPAT 137:353320

AB Compds. B-L-A-N(D)COCO2P2 [A are rings of defined structure; B = H, alkyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl; D = substituted Ph, alkyl, or 1-alkenyl [the substituent at the o- or 2-position is alkoxy, alkyl, sulfamoyl, amino, cyano, nitro, CO2P1, SO3H, P(O)(OH)2, CH2P(O)(OH)2, CHFP(O)(OH)2, CF2P(O)(OH)2, or C(:NH)NH2] or certain 5-membered heterocycles; P1, P2 = H, alkyl, alkenyl, arylalkyl, cycloalkyl, cycloalkylalkyl; L = (un)substituted (hetero)alkylene] or their therapeutically acceptable salts were prepd. as protein tyrosine kinase 1B (PTP1B) inhibitors. Thus, N-[5-[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl]amino]pentanoyl-L-methionine and Me 2-[4-[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenylalanyl]amino]butoxy]-6-hydroxybenzoate were prepd. and showed Kic = 0.077 .+-. 0.012 and 0.016 .+-. 0.003 .mu.M, resp., for inhibition of PTP1B.


IT 436864-07-2P 436864-18-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino(oxo)acetic acid derivs. as selective protein tyrosine phosphatase inhibitors)


RN 436864-07-2 CAPLUS

CN Benzoic acid, 2-[4-[[2-(acetylamino)-3-[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 436864-18-5 CAPLUS

CN Benzoic acid, 2-[4-[[2-(acetylamino)-3-[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl]-1-oxopropyl]amino]butoxy]-6-hydroxy-(9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:450342 CAPLUS

DOCUMENT NUMBER: 137:33535

TITLE: Preparation of amino(oxo)acetic acids as selective protein tyrosine phosphatase inhibitors

INVENTOR(S): Liu, Gang; Szczepankiewicz, Bruce G.; Pei, Zhonghua; Xin, Zhili; Janowick, David A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 918,928.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002072516	A1	20020613	US 2001-941471	20010829
US 2002035137	A1	20020321	US 2001-918928	20010731
US 2002169157	A1	20021114	US 2002-85157	20020227
WO 2003020688	A1	20030313	WO 2002-US24506	20020801

W: CA, JP, MX

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR

PRIORITY APPLN. INFO.:
 US 2000-228651P P 20000829
 US 2000-650922 A2 20000829
 US 2001-918928 A2 20010731
 US 2001-941471 A2 20010829

OTHER SOURCE(S): MARPAT 137:33535

AB Compds. B-L-A-N(D)COCO2P2 [A are rings of defined structure; B = H, alkyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl; D = substituted Ph, alkyl, or 1-alkenyl, in which the substituent at the o- or 2-position is alkoxy, alkyl, amino, cyano, nitro, CO2P1, SO3H, P(O)(OH)2, CH2P(O)(OH)2, CF2P(O)(OH)2, C(:NH)NH2, or certain 5-membered heterocycles; P1, P2 = H, alkyl, alkenyl, arylalkyl, cycloalkyl, cycloalkylalkyl; L = (un)substituted (hetero)alkylene] or their therapeutically acceptable salts were prepd. as protein tyrosine kinase 1B (PTP1B) inhibitors. Thus, N-[5-[[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl]amino]pentanoyl]-L-methionine and Me

2-[4-[N-acetyl-4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl]amino]butoxy]-6-hydroxybenzoate were prepd. and showed $K_{ic} = 0.077 \pm 0.012$ and $0.016 \pm 0.003 \mu M$, resp., for inhibition of PTP1B.


IT 436864-07-2P 436864-18-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino(oxo)acetic acids as selective protein tyrosine phosphatase inhibitors)


RN 436864-07-2 CAPLUS

CN Benzoic acid, 2-[4-[2-(acetyl-amino)-3-[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl]-1-oxopropyl]amino]butoxy]-6-hydroxy-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 436864-18-5 CAPLUS

CN Benzoic acid, 2-[4-[2-(acetyl-amino)-3-[4-[(carboxycarbonyl)(2-carboxyphenyl)amino]-3-ethylphenyl]-1-oxopropyl]amino]butoxy]-6-hydroxy-, (9CI) (CA INDEX NAME)



=>